Dr. Ravaud has received consultant fees and speaking fees (less than $10,000 each) from Roche, GlaxoSmithKline, Pfizer, Laboratoires Servier, and Sanofi-Aventis.
Reporting of corticosteroid use in systemic disease trials: Evidence from a systematic review of the potential impact on treatment effect
Article first published online: 23 FEB 2010
Copyright © 2010 by the American College of Rheumatology
Arthritis Care & Research
Volume 62, Issue 7, pages 1002–1008, July 2010
How to Cite
Pagnoux, C., Dechartres, A., Giraudeau, B., Seror, R., Guillevin, L. and Ravaud, P. (2010), Reporting of corticosteroid use in systemic disease trials: Evidence from a systematic review of the potential impact on treatment effect. Arthritis Care Res, 62: 1002–1008. doi: 10.1002/acr.20139
- Issue published online: 29 JUN 2010
- Article first published online: 23 FEB 2010
- Manuscript Accepted: 8 FEB 2010
- Manuscript Received: 25 AUG 2009
Additional Supporting Information may be found in the online version of this article.
|ACR_20139_sm_appenda.doc||32K||SUPPLEMENTARY APPENDIX A: DETAILED STATISTICAL ANALYSIS FOR ADJUSTMENT ON CORTICOSTEROID CONSUMPTION|
|ACR_20139_sm_appendb.doc||61K||SUPPLEMENTARY APPENDIX B: COMPLETE REFERENCE LIST OF THE SELECTED RANDOMIZED TRIALS, FOR EACH DISEASE SEPARATELY LUPUS|
|ACR_20139_sm_appendc.doc||14689K||SUPPLEMENTARY APPENDIX C: RESULTS OF 24 STUDIES|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.